{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:01:24Z","timestamp":1793192484812,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40265-025-02163-3","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T21:58:39Z","timestamp":1742421519000},"page":"707-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Zanidatamab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2163_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2024.107695","volume":"151","author":"M Bhagyalalitha","year":"2024","unstructured":"Bhagyalalitha M, Shankaranarayana AH, Kumar SA, et al. Advances in HER2-targeted therapies: from monoclonal antibodies to dual inhibitors developments in cancer treatment. Bioorg Chem. 2024;151:1\u201321.","journal-title":"Bioorg Chem"},{"key":"2163_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215180","author":"JE Rogers","year":"2023","unstructured":"Rogers JE, Yamashita K, Sewastjanow-Silva M, et al. Human epidermal growth factor receptor-2 gastric adenocarcinoma: expanding therapy of a recognized target. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15215180.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2163_CR3","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser NE, Sanches M, Escobar-Cabrera E, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14(1):1394.","journal-title":"Nat Commun"},{"issue":"12","key":"2163_CR4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","volume":"23","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Beeram M, Hamilton E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23(12):1558\u201370.","journal-title":"Lancet Oncol"},{"key":"2163_CR5","unstructured":"BeiGene Ltd. Zymeworks and BeiGene announce license and collaboration agreement for Zymeworks' HER2-targeted therapeutic candidates, ZW25 and ZW49, in Asia-Pacific and research and license agreement for Zymeworks' AzymetricTM and EFECTTM platforms globally [media release]. 27 Nov 2018. https:\/\/www.zymeworks.com."},{"key":"2163_CR6","unstructured":"Jazz Pharmaceuticals Inc. Jazz Pharmaceuticals and Zymeworks announce exclusive license agreement to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody [media release]. 19 Oct 2022. https:\/\/www.jazzpharma.com."},{"key":"2163_CR7","unstructured":"Jazz Pharmaceuticals Inc. Zanidatamab: US prescribing information. 2024. https:\/\/ziihera.com\/. Accessed 12 Dec 2024."},{"key":"2163_CR8","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer [media release]. 21 Nov 2024. https:\/\/www.fda.gov\/."},{"key":"2163_CR9","unstructured":"Jazz Pharmaceuticals Inc. Jazz Pharmaceuticals announces US FDA approval of Ziihera\u00ae (zanidatamab- hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) [media release]. 20 Nov 2024. https:\/\/www.jazzpharmaceuticals.com."},{"key":"2163_CR10","unstructured":"European Medicines Agency. Applications for new human medicines under evaluation: July 2024. 2024. https:\/\/www.ema.europa.eu\/. Accessed 11 Dec 2024."},{"key":"2163_CR11","unstructured":"Zymeworks Inc. Zymeworks announces China NMPA acceptance of Biologics License Application for Zanidatamab for second-line treatment of biliary tract cancer [media release]. 10 June 2024. https:\/\/www.zymeworks.com."},{"key":"2163_CR12","unstructured":"Jazz Pharmaceuticals Inc. Jazz Pharmaceuticals and Zymeworks announce Jazz has confirmed opt-in and advances partnership for zanidatamab [media release]. 21 Dec 2022. https:\/\/www.jazzpharmaceuticals.com."},{"issue":"5","key":"2163_CR13","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/2159-8290.CD-23-0838","volume":"14","author":"TP DiPeri","year":"2024","unstructured":"DiPeri TP, Evans KW, Wang B, et al. Co-clinical trial of novel bispecific anti-HER2 antibody zanidatamab in patient-derived xenografts. Cancer Discov. 2024;14(5):828\u201345.","journal-title":"Cancer Discov"},{"issue":"7","key":"2163_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772\u201382.","journal-title":"Lancet Oncol"},{"key":"2163_CR15","doi-asserted-by":"crossref","unstructured":"Pant S, Fan J, Oh D-Y, et al. Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study [abstract no. 4091 plus poster]. J Clin Oncol. 2024;42(16 Suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.4091"},{"issue":"Suppl 2","key":"2163_CR16","doi-asserted-by":"publisher","first-page":"S887","DOI":"10.1016\/j.annonc.2024.08.1489","volume":"35","author":"E Elimova","year":"2024","unstructured":"Elimova E, Ajani JA, Burris HA, et al. Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): new and updated data from a phase II trial [abstract no. 1423P plus poster]. Ann Oncol. 2024;35(Suppl 2):S887\u20138.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2163_CR17","doi-asserted-by":"publisher","first-page":"S855","DOI":"10.1016\/j.annonc.2023.09.1431","volume":"34","author":"KW Lee","year":"2023","unstructured":"Lee KW, Bai LY, Jung M, et al. Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric\/gastroesophageal junction adenocarcinoma (GC\/GEJC): updated results from a phase Ib\/II study [abstract no. 1518P]. Ann Oncol. 2023;34(Suppl 2):S855\u20136.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2163_CR18","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.1016\/j.annonc.2024.08.585","volume":"35","author":"SY Rha","year":"2024","unstructured":"Rha SY, Lee K-W, Lee S, et al. Zanidatamab (Zani) + chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+) advanced\/metastatic colorectal cancer (mCRC) [abstract no. 516MO and presentation]. Ann Oncol. 2024;35(Suppl 2):S436\u20137.","journal-title":"Ann Oncol"},{"key":"2163_CR19","doi-asserted-by":"crossref","unstructured":"Escriv\u00e1-de-Romani S, Cejalvo JM, Alba E, et al. Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+\/HR+ metastatic breast cancer (mBC) [abstract no. LBO1-04 plus poster]. Cancer Res. 2024;84(9 Suppl).","DOI":"10.1158\/1538-7445.SABCS23-LBO1-04"},{"key":"2163_CR20","doi-asserted-by":"crossref","unstructured":"Wang X, Lee KS, Zeng X, et al. Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib\/II study [abstract no. 1]. J Clin Oncol. 2023;41(Suppl 1).","DOI":"10.1200\/JCO.2023.41.16_suppl.1044"},{"key":"2163_CR21","doi-asserted-by":"crossref","unstructured":"Bedard PL, Im SA, Elimova E, et al. Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study [abstract no. P2-13-07]. Cancer Res. 2022;82(4 Suppl).","DOI":"10.1158\/1538-7445.SABCS21-P2-13-07"},{"key":"2163_CR22","doi-asserted-by":"crossref","unstructured":"Valero V, Mouabbi J, Alonzo H, et al. Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer [abstract no. PS09-03 plus poster]. Cancer Res. 2024;84(9 Suppl).","DOI":"10.1158\/1538-7445.SABCS23-PS09-03"},{"key":"2163_CR23","unstructured":"Montero A. Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: results from a phase 1b\/2 study [abstract no. PS8-09 plus poster]. In: San Antonio Breast Cancer Symposium. 2024."},{"issue":"Suppl 3","key":"2163_CR24","doi-asserted-by":"publisher","first-page":"S1318","DOI":"10.1016\/j.annonc.2024.07.643","volume":"35","author":"T Doi","year":"2024","unstructured":"Doi T, Muro K, Nishina T, et al. A phase 1 study of zanidatamab monotherapy in Japanese patients with metastatic or unresectable HER2-expressing cancers [abstract no. O7\u20134]. Ann Oncol. 2024;35(Suppl 3):S1318\u20139.","journal-title":"Ann Oncol"},{"key":"2163_CR25","unstructured":"Roche Diagnostics. Roche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA [media release]. 25 Nov 2024. https:\/\/diagnostics.roche.com\/."},{"issue":"Suppl 2","key":"2163_CR26","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1016\/j.annonc.2024.08.2078","volume":"35","author":"TM Mercade","year":"2024","unstructured":"Mercade TM, Harding JJ, Pant S, et al. HERIZON-BTC-302: a phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced\/metastatic biliary tract cancer (BTC) [abstract no. 62TiP]. Ann Oncol. 2024;35(Suppl 2):S237.","journal-title":"Ann Oncol"},{"issue":"29","key":"2163_CR27","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.2217\/fon-2022-0595","volume":"18","author":"J Tabernero","year":"2022","unstructured":"Tabernero J, Shen L, Elimova E, et al. HERIZON-GEA-01: zanidatamab + chemo \u00b1 tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022;18(29):3255\u201366.","journal-title":"Future Oncol"},{"key":"2163_CR28","unstructured":"Tolaney SM, Cortes J, Hamilton E, et al. EmpowHER 303: a phase 3 study to evaluate the efficacy and safety of zanidatamab vs trastuzumab with chemotherapy in patients (pts) with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan [abstract no. P5-03-15 plus poster]. In: San Antonio Breast Cancer Symposium. 2024."},{"key":"2163_CR29","doi-asserted-by":"crossref","unstructured":"Pohlmann PR, Potter DA, Chen N, et al. PRE-ISPY phase I\/Ib oncology platform program (PRE-I-SPY-P1) [abstract no. e12641]. J Clin Oncol. 2024;42(16 Suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.e12641"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02163-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:52:06Z","timestamp":1745556726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02163-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2163"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02163-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}